news.med.miami.edu
Jun 16, 2025, 02:06
C. Ola Landgren: Presenting ADVANCE Trial Results in Multiple Myeloma at EHA25
C. Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:
“Thank you, EHA25, for inviting me to present our results from the randomized, multicenter ADVANCE clinical trial for the treatment of patients with newly diagnosed multiple myeloma – at the annual meeting in Milan, Italy!
The study shows that the 4-drug combination with Daratumumab-Carfilzomib-Lenalidomide-dexamethasone (Dara-KRd) delivers significantly (p<0.0001; OR=2.9) higher MRD negativity rates compared to KRd. The results are consistent across subgroups.
The progression-free survival analysis shows that at almost 3 years of follow-up, 92% of the patients treated with Dara-KRd) are are doing well and are free from progression. The study was open for enrollment, independent of transplant eligibility (transplant eligible, transplant ineligible, and transplant deferred). MRD negativity after 8 cycles of combination therapy was the primary endpoint. There were no new safety signals.
We conclude that Dara-KRd is a new standard of care for newly diagnosed multiple myeloma patients, independent of transplant eligibility.
Thank you to all patients and family who participated in the ADVANCE clinical trial for newly diagnosed multiple myeloma! Thank you to all our collaborators and thank you to our funding support!”
More posts from EHA 2025.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals
Sep 29, 2025, 12:54
Sep 29, 2025, 12:33
Sep 29, 2025, 06:23
Sep 29, 2025, 05:06
Sep 29, 2025, 04:28